EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild‐to‐moderate atopic dermatitis

Lin Ma, Litao Zhang iD, Michiko Kobayashi, Xiaohua Tao, Qiufang Qian, Hao Cheng, Sujun Liu iD, Yangmei Zhou, Yayuan Chen, Jianzhong Zhang iD

The Journal of Dermatology · 2023

DOI: 10.1111/1346-8138.16792 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Dermatology, 2023. Verfasst von Lin Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc., Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atopic dermatitis is a chronic inflammatory skin disease with a significant impact on the overall wellbeing of patients and their families. Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor approved for the treatment of mild‐to‐moderate atopic dermatitis in multiple countries. However, in the key pivotal trials, a low proportion of the overall patient population was Asian, therefore the safety and efficacy of crisaborole in the Asian population with atopic dermatitis remains unclear. CrisADe CLEAR was a multicenter, randomized, double‐blind, vehicle‐controlled, phase 3 study (NCT04360187) to assess the efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild‐to‐moderate atopic dermatitis involving ≥5% treatable body surface area. Patients were randomly assigned 2:1 to receive crisaborole or vehicle twice daily for 28 days. The primary endpoint was percentage change from baseline in the Eczema Area and Severity Index total score at day 29. Additional endpoints were improvement and success per Investigator's Static Global Assessment score at day 29 and change from baseline on the Peak Pruritus Numerical Rating Scale at week 4. Safety was assessed using rates of treatment emergent adverse events, serious adverse events, and clinically significant changes in vital signs and clinical laboratory parameters. Crisaborole‐treated patients showed a significantly greater reduction versus vehicle in percentage change from baseline in Eczema Area and Severity Index total score at day 29 ( P = 0.0002). Response rates for achievement of Investigator's Static Global Assessment improvement and success at day 29 were significantly higher for patients treated with crisaborole versus vehicle ( P = 0.0124 and P = 0.0078, respectively). Crisaborole‐treated patients showed a significantly greater reduction versus vehicle in change from baseline on the Peak Pruritus Numerical Rating Scale at week 4 ( P = 0.0009). No new safety signals were identified. Treatment with crisaborole was effective and well tolerated in Chinese and Japanese patients with mild‐to‐moderate atopic dermatitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansDouble-Blind MethodEast Asian PeopleEczemaOintmentsPruritusSeverity of Illness IndexSkin DiseasesTreatment OutcomeChronic DiseasePhosphodiesterase 4 InhibitorsBoron CompoundsBridged Bicyclo Compounds, Heterocyclic

Stichwörter der Autor:innen

Asian populationatopic dermatitiscrisaboroleefficacysafety

Substanzen

OintmentsPhosphodiesterase 4 InhibitorscrisaboroleBoron CompoundsBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
  • Sugamo Kobayashi Derma Clinic, Tokyo, Japan.
  • Zhejiang Provincial People's Hospital, Zhejiang, China.
  • Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Zhejiang, China.

ORCID-Profile: Litao Zhang, Sujun Liu, Jianzhong Zhang

Förderung

  • Pfizer Inc.
  • Pfizer

Zitieren

APA

Ma, L., Zhang, L., Kobayashi, M., Tao, X., Qian, Q., Cheng, H., Liu, S., Zhou, Y., Chen, Y., & Zhang, J. (2023). Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild‐to‐moderate atopic dermatitis. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.16792

Vancouver

Ma L, Zhang L, Kobayashi M, Tao X, Qian Q, Cheng H, et al. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild‐to‐moderate atopic dermatitis. The Journal of Dermatology. 2023. doi:10.1111/1346-8138.16792

BibTeX
@article{Ma2023,
  author = {Ma, Lin and Zhang, Litao and Kobayashi, Michiko and Tao, Xiaohua and Qian, Qiufang and Cheng, Hao and Liu, Sujun and Zhou, Yangmei and Chen, Yayuan and Zhang, Jianzhong},
  title = {Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild‐to‐moderate atopic dermatitis},
  journal = {The Journal of Dermatology},
  year = {2023},
  doi = {10.1111/1346-8138.16792}
}
Kostenlos starten →